1681 — Consun Pharmaceutical Cashflow Statement
0.000.00%
Last trade - 00:00- HK$14.36bn
- HK$10.51bn
- CNY3.42bn
Annual cashflow statement for Consun Pharmaceutical, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | — |
| Source: | ARS | ARS | ARS | ARS | |
| Standards: | HKAS | HKAS | HKAS | HKAS | — |
| Status: | Final | Final | Final | Final | fx Preliminary |
| Net Income/Starting Line | 696 | 746 | 864 | 1,020 | — |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | -6.42 | -40 | -37.8 | -53.3 | — |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -36.9 | 165 | -84.5 | 56.7 | — |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 726 | 948 | 819 | 1,087 | — |
| Capital Expenditures | -98.3 | -51.6 | -52.6 | -109 | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -200 | -317 | -179 | -77.9 | — |
| Sale of Fixed Assets | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -298 | -369 | -232 | -187 | — |
| Financing Cash Flow Items | -12.9 | -10.9 | -27.5 | 68.9 | — |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -167 | -342 | -280 | -729 | — |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 256 | 254 | 298 | 159 | — |